Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows

Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows
Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free survival times than those given chemotherapy, full results from the SOLO-3 Phase 3 trial show. These findings make Lynparza the first and only PARP inhibitor to outperform standard chemotherapy in this patient group, AstraZeneca and Merck (known as MSD outside North America), which jointly develop Lynparza, announced in a press release. An oral presentation at the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, titled “Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial,” detailed the results. SOLO-3 (NCT02282020) was a randomized, open-label and placebo-controlled study evaluating if Lynparza is better than chemotherapy at treating germline (inherited) BRCA-mutated advanced ovarian cancer. It enrolled 266 women who had already undergone two prior
Subscribe or to access all post and page content.